|1.||Balfour, H H: 1 article (08/2000)|
|2.||Fletcher, C V: 1 article (08/2000)|
|3.||Henry, K: 1 article (08/2000)|
|4.||Anderson, P L: 1 article (08/2000)|
|5.||Brundage, R C: 1 article (08/2000)|
|6.||Noormohamed, S E: 1 article (08/2000)|
08/01/2000 - "Semen and serum pharmacokinetics of zidovudine and zidovudine-glucuronide in men with HIV-1 infection."
07/01/1998 - "Zidovudine (3'-azido-3'-deoxythymidine [AZT]), an antiviral nucleoside analog effective in the treatment of human immunodeficiency virus infection, is primarily metabolized to an inactive glucuronide form, GAZT, via uridine-5'-diphospho-glucuronosyltransferase (UGT) enzymes. "
06/01/1990 - "The reason for such a decrease in oral clearance of zidovudine was the reduction in the GAZT formation clearance (236 +/- 73 versus 1540 +/- 540 ml/min); this led to a decrease in the AUC ratio of GAZT and zidovudine (1.3 +/- 0.6 versus 4.6 +/- 0.7), which was directly related to the severity of the cirrhosis. "
|3.||Chronic Kidney Failure (Chronic Renal Failure)
11/01/1995 - "The enterohepatic metabolism of AZT, the effect of such a dosing schedule and the effects of circulating levels of GAZT on outcomes in HIV-infected patients with ESRD must be further investigated."
11/01/1995 - "Serum levels of GAZT were higher in ESRD patients at 90 min, and by 4 h were more than an order of magnitude greater than normal controls. "
11/01/1989 - "In patients with end stage renal disease, the AZT elimination half-life is slightly increased (1.9 h) while for GAZT the very important increase of this parameter results in a major risk of accumulation. "
11/01/1995 - "We determined the pharmacokinetics of zidovudine (AZT) and its metabolite (GAZT) in HIV-infected patients with end-stage renal disease (ESRD), between dialysis sessions, and compared these to HIV-infected patients with normal renal function. "
|4.||Body Weight (Weight, Body)
05/01/1991 - "The pharmacokinetics and metabolism of 3'-azido-3'-deoxythymidine (AZT) were investigated in rhesus monkeys after subcutaneous administration of 33.3 mg of AZT per kg of body weight alone or in the presence of 100 mg of probenecid per kg. In addition to unchanged drug, two catabolites, 5'-O-glucuronide (GAZT) and 3'-amino-3'-deoxythymidine (AMT), were detected in plasma within 30 min. GAZT exhibited a kinetic profile similar to that of AZT, with an elimination half-life of approximately 1 h, while AMT was more variable, with an apparent half-life of 1.6 +/- 1.5 h. "
|5.||Acquired Immunodeficiency Syndrome (AIDS)